Cocrystal Pharma
COCP
25 hedge funds and large institutions have $11.9M invested in Cocrystal Pharma in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 8 increasing their positions, 3 reducing their positions, and 5 closing their positions.
167% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 3
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
42% more capital invested
Capital invested by funds: $8.39M → $11.9M (+$3.53M)
19% more funds holding
Funds holding: 21 → 25 (+4)
0.73% more ownership
Funds ownership: 0.88% → 1.61% (+0.73%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.34M |
| 2 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.06M |
| 3 |
Renaissance Technologies
New York
|
+$1.15M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$634K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$290K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EU
Emory University
Atlanta,
Georgia
|
-$232K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$25.8K |
| 3 |
Squarepoint
New York
|
-$16K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.7K |
| 5 |
TI
tru Independence
Portland,
Oregon
|
-$5K |
COCP Hedge Fund Activity: Q3 2020 in Review
25 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Cocrystal Pharma (COCP) for Q3 2020, worth a combined $11.9M — up 42% from $8.39M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new COCP positions and 5 closed out — a net gain of 4 holders — while 8 added to existing stakes and 3 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.34M. The largest seller was Emory University, exiting entirely with an estimated $232K sold.
- 25 institutional investors held Cocrystal Pharma (COCP) as of Q3 2020, up from 21 in Q2 2020.
- Funds reported $11.9M of Cocrystal Pharma stock for Q3 2020, up 42% quarter-over-quarter.
- 9 funds opened new Cocrystal Pharma positions in Q3 2020 and 5 closed out, a net change of +4 holders.
- The largest Cocrystal Pharma buyer in Q3 2020 was Point72 Asset Management, an estimated $4.34M added.
- The largest Cocrystal Pharma seller in Q3 2020 was Emory University, an estimated $232K sold.
Based on aggregated 13F filings for Q3 2020.